Result of AGM

RNS Number : 5117X

SkinBioTherapeutics PLC

19 December 2019

 

SkinBioTherapeutics plc

(the "Company")

Result of AGM

SkinBioTherapeutics plc (AIM: SBTX), announces that at the Company's Annual General Meeting, held earlier today, all resolutions were duly passed.

For more information, please contact:

SkinBioTherapeutics plc Stuart Ashman, CEO Doug Quinn, CFO	Tel: [phone]
Cairn Financial Advisers LLP (Nominated Adviser) Tony Rawlinson / Sandy Jamieson	Tel: [phone]
SP Angel Corporate Finance (Joint Broker) Vadim Alexandre / Abigail Wayne	Tel: [phone]
Turner Pope Investments (Joint Broker) Andy Thacker / Zoe Alexander	Tel: [phone]
Instinctif Partners Melanie Toyne-Sewell / Phil Marriage / Nathan Billis	Tel: [phone]    [e-mail]

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by Dr. Catherine O'Neill and Professor Andrew McBain.

The Company has demonstrated, through scientific testing, that the SkinBiotix® platform can improve the barrier effect of skin models, protect from infection and repair wounds. Proof of principle studies have also shown that the SkinBiotix® platform has beneficial attributes applicable to each of these areas. The technology achieved positive results in clinical studies in human volunteers in early 2019.

The Company listed on AIM in April 2017 and is based in Manchester, UK.  For more information, visit: www.skinbiotherapeutics.com.  

 

END

 

 

RAGCKCDQDBDDABD